GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) — Greater Cannabis Company, Inc. (GCANRx or the Company) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid thera…